Posted: 21 February 2018

Outstanding aspartame experts have spoken out against the poison aspartame since the beginning. Today as autism has increased 2500%. the FDA continues to ignore all the records. Read how G. D. Searle made a deal with the FDA to seal the teratology studies so the public wouldn't know aspartame triggers birth defects http://www.rense.com/general96/asparautism.html

This chapter on autism is from the medical text on aspartame and methanol, "While Science Sleeps: A Sweetener Kills" by Dr. Woodrow Monte. The report below needs to be added to many web sites to alert pregnant women to never use aspartame. The original studies sealed from the records by FDA for decades showed neural tube defects, spina bifida and cleft palate for starters! See the Bressler Report http://www.mpwhi.com/complete_bressler_report.pdf to read the FDA records they tried to hide from public view.

2040 Ridgewood Drive, N.E. Atlanta, Georgia 30322
(404) 727-5840

Statement for the Labor and Human Resources Committee, U.S. Senate

I have considerable concern for the increased dissemination and consumption of the sweetener, aspartame, (1-methyl N-L-a-aspartyl-L-phenylalanine) in our world food supply. This artificial dipeptide is hydrolyzed by the intestinal tract to produce L-phenylalanine which in excess is a known neurotoxin. Normal humans do not metabolize phenylalanine as efficiently as do lower species such as rodents and thus most of the previous studies in Aspartame effects on rats are irrelevant to the question, "does phenylalanine excess occur with Aspartame ingestion?".

Preliminary studies in my laboratory provide tentative positive answers to both questions. Many studies of both acute and chronic ingestion of 34mg Aspartame/kg/day have demonstrated a two to five fold increase in semi-fasting blood phenylalanine concentrations (from approximately 50 to 250 M) without concomitant increases in tyrosine or other aminoacids. The degree of increase by normal humans depends on several variables including the efficiency of tut transport, liver utilization, and growth rates. It was thought by many scientists and clinicians that this degree of phenylalanine increase would not affect brain function. However, currently available information indicates that this is not true.

  1. In the developing fetus such a rise in material blood phenylalanine could be magnified four to six fold by the concentrative efforts of the placenta and fetal blood brain barrier. Thus a maternal phenylalanine of 150 M could reach 900 M in the developing fetal brain] cell and this concentration kills such cells in tissue culture. The effect of such an increased fetal brain concentrations in vivo would probably be much more subtle and expressed as mental retardation, microcephaly, or potential certain birth defects.
  2. In the rapidly growing post-natal bran (children of 0-12 months) irreversible brain damage could occur by the same mechanism.
  3. In the adult we have found that changes in blood phenylalanine in these concentration ranges are associated with slowing of the electroencephalogram, and prolongation of cognitive function tests. Fortunately, these effects on the mature brain are reversible but provide clear evidence for negative effect on sensitive parameters of brain function.
In view of these new (and confirmation of old) research findings I suggest the following:

  1. Immediate labeling of all aspartame-containing foods, so the consumer will know how much phenylalanine he/she is ingesting.

  2. Declare an immediate moratorium on addition of aspartame to more foods and remove it from all low-protein beverages, foods, and children's medications.
  3. Provide funds not controlled by industry to:
    1. Allow active surveillance for potential side-effects of aspartame on newborns whose mothers dieted with Nutrasweet (aspartame) -containing foods.
    2. Allow active evaluation of other users whose complaints cannot be adequately studied at present.
    3. Clarify the dose relationship and mechanisms by which L-phenylalanine affects human brain function.
Respectfully submitted

Louis J. Elsas, II, M.D.
Director, Division of Medical Genetics
Professor of Pediatrics


The above statement was before the Committee of Labor and Human Resources on the subject "Nutrasweet: Health and safety concerns", and dated November 3, 1987.